{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T19:35:27Z","timestamp":1774294527294,"version":"3.50.1"},"reference-count":43,"publisher":"Informa UK Limited","issue":"12","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Clinical Toxicology"],"published-print":{"date-parts":[[2023,12,2]]},"DOI":"10.1080\/15563650.2023.2294619","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T05:51:53Z","timestamp":1706161913000},"page":"1013-1016","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":20,"title":["Closing the xylazine knowledge gap"],"prefix":"10.1080","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0091-9573","authenticated-orcid":false,"given":"Robert S.","family":"Hoffman","sequence":"first","affiliation":[{"name":"Division of Medical Toxicology, Ronald O. Perelman Department of Emergency Medicine, NYU Grossman School of Medicine","place":["New York, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,1,25]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00539619"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00622991"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00537424"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2885.1988.tb00189.x"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-0813.1972.tb02228.x"},{"key":"e_1_3_2_7_1","volume-title":"AnaSed\u00ae (xylazine hydrochloride) [prescribing information]","year":"2022","unstructured":"AnaSed\u00ae (xylazine hydrochloride) [prescribing information]. Gurnee, IL: Akorn Operating Company LLC; 2022."},{"key":"e_1_3_2_8_1","volume-title":"Anada\u00ae (xylazine) [prescribing information]","year":"2020","unstructured":"Anada\u00ae (xylazine) [prescribing information]. Dublin, OH: Covetrus; 2020."},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0195-5616(99)50058-2"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/1747-597X-6-7"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7226a4"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7037a4"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1101\/2023.08.24.23294567"},{"key":"e_1_3_2_14_1","unstructured":"Health Canada. Spotlight: the emergence of Xylazine in Canada; 2023 [cited 2023 Dec 6]. Available from: https:\/\/www.canada.ca\/en\/health-canada\/services\/publications\/healthy-living\/emergence-xylazine-canada.html"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jflm.2023.102542"},{"key":"e_1_3_2_16_1","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. The drug situation in Europe up to 2023 \u2013 an overview and assessment of emerging threats and new developments (European Drug Report 2023). 2023 [cited 2023 Dec 13]. Available from: https:\/\/www.emcdda.europa.eu\/publications\/european-drug-report\/2023\/drug-situation-in-europe-up-to-2023_en"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.4103\/tjem.tjem_198_22"},{"key":"e_1_3_2_18_1","unstructured":"National Institutes of Health. Xylazine appears to worsen the life-threatening effects of opioids in rats. 2023 [cited 2023 Dec 6]. Available from: https:\/\/www.nih.gov\/news-events\/news-releases\/xylazine-appears-worsen-life-threatening-effects-opioids-rats"},{"key":"e_1_3_2_19_1","unstructured":"United States Drug Enforcement Administration. DEA reports widespread threat of fentanyl mixed with xylazine. 2023 [cited 2023 Dec 6]. Available from: https:\/\/www.dea.gov\/alert\/dea-reports-widespread-threat-fentanyl-mixed-xylazine"},{"key":"e_1_3_2_20_1","unstructured":"The White House Office of National Drug Control Policy. Biden-Harris administration designates fentanyl combined with xylazine as an emerging threat to the United States Washington DC. 2023 [cited 2023 Dec 6]. Available from: https:\/\/www.whitehouse.gov\/ondcp\/briefing-room\/2023\/04\/12\/biden-harris-administration-designates-fentanyl-combined-with-xylazine-as-an-emerging-threat-to-the-united-states\/"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/25.4.245"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/0735-6757(86)90070-7"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.3109\/15563658108990293"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.66.773.244"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2014.03.015"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0379-0738(03)00083-5"},{"issue":"6","key":"e_1_3_2_27_1","first-page":"324","article-title":"An unusual presentation from xylazine-ketamine","volume":"46","author":"Arican FO","year":"2004","unstructured":"Arican FO, Okan T, Badak O, et\u00a0al. An unusual presentation from xylazine-ketamine. Vet Hum Toxicol. 2004;46(6):324\u2013325.","journal-title":"Vet Hum Toxicol"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMicm2303601"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.28160"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2016.02.007"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12024-018-9967-9"},{"key":"e_1_3_2_32_1","unstructured":"CNN. Flesh-eating \u2018zombie\u2019 drug \u2018kills you from the inside out\u2019. 2013 [cited 2023 Dec 6]. Available from: https:\/\/www.cnn.com\/2013\/10\/16\/health\/krokodil-zombie-drug\/index.html"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(50)90021-0"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-198401000-00016"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.133.8.812"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.110833"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2022.100074"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2023.07.025"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104154"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2022.2063135"},{"issue":"7","key":"e_1_3_2_41_1","first-page":"811","article-title":"Profound QT prolongation after attempted suicide with intravenous xylazine hydrochloride","volume":"52","author":"Snow J","year":"2014","unstructured":"Snow J, Kao L, Williams K. Profound QT prolongation after attempted suicide with intravenous xylazine hydrochloride. Clin Toxicol. 2014;52(7):811.","journal-title":"Clin Toxicol"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2015.09.051"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2022.2159427"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2023.2288540"}],"container-title":["Clinical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/15563650.2023.2294619","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T16:22:48Z","timestamp":1762273368000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/15563650.2023.2294619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,2]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12,2]]}},"alternative-id":["10.1080\/15563650.2023.2294619"],"URL":"https:\/\/doi.org\/10.1080\/15563650.2023.2294619","relation":{},"ISSN":["1556-3650","1556-9519"],"issn-type":[{"value":"1556-3650","type":"print"},{"value":"1556-9519","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ictx20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ictx20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-01-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}